The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
Open accessAbstract
Background Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA). Methods A multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another systemic antifungal agent. Criteria for IA and therapeutic responses were judged by an independent panel. Results Of the 331 patients enrolled, only 225 met diagnostic criteria for IA as determined by the independent panel and received at least one dose of micafungin. Patients included 98/225 who had undergone hematopoietic stem cell transplantation (HSCT) (88/98 allogeneic), 48 with graft versus host disease (GVHD), and 83/225 who had received chemotherapy for hematologic malignancy. A favorable response rate at the end of therapy was seen in 35.6% (80/225) of patients. Of those only treated with micafungin, favorable responses were seen in 6/12 (50%) of the primary and 9/22 (40.9%) of the salvage therapy group, with corresponding numbers in the combination treatment groups of 5/17 (29.4%) and 60/174 (34.5%) of the primary and salvage treatment groups, respectively. Of the 326 micafungin-treated patients, 183 (56.1%) died during therapy or in the 6-week follow-up phase; 107 (58.5%) deaths were attributable to IA. Conclusions Micafungin as primary or salvage therapy proved efficacious and safe in high-risk patients with IA, although patient numbers are small in the micafungin-only groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Self-citationAntifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Self-citationEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Self-citationInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Self-citationvan Burik, J.-A. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J. W., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 744
Self-citationTherapeutic Outcome in Invasive Aspergillosis
Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.608 · Cited by 689
Self-citationMaertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Self-citationCaillot, D., Couaillier, J.-F., Bernard, A., Casasnovas, O., Denning, D. W., Mannone, L., Lopez, J., Couillault, G., Piard, F., Vagner, O., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.253 · Cited by 587
Self-citationInvasive aspergillosis in critically ill patients without malignancy
Meersseman, W., Vandecasteele, S. J., Wilmer, A., Verbeken, E., Peetermans, W. E., & Van Wijngaerden, E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-093oc · Cited by 547
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Fukuda, T., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Martin, P. J., Storb, R. F., & Marr, K. A. (2003) · Blood · doi:10.1182/blood-2003-02-0456 · Cited by 465
Self-citationNIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90023-x · Cited by 450
Self-citationMinari, A., Husni, R., Avery, R. K., Longworth, D. L., DeCamp, M., Bertin, M., Schilz, R., Smedira, N., Haug, M. T., Mehta, A., et al. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.t01-2-02002.x · Cited by 351
Bowden, R., Chandrasekar, P., White, M. H., Li, X., Pietrelli, L., Gurwith, M., van Burik, J., Laverdiere, M., Safrin, S., & Wingard, J. R. (2002) · Clinical Infectious Diseases · doi:10.1086/341401 · Cited by 335
Self-citationMarr, K. A., Patterson, T., & Denning, D. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00035-1 · Cited by 307
Self-citationSingh, N., & Husain, S. (2003) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(02)00477-1 · Cited by 293
Kontoyiannis, D. P., Hachem, R., Lewis, R. E., Rivero, G. A., Torres, H. A., Thornby, J., Champlin, R., Kantarjian, H., Bodey, G. P., & Raad, I. I. (2003) · Cancer · doi:10.1002/cncr.11479 · Cited by 287
Junghanss, C., Marr, K. A., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Chauncey, T., McSweeney, P. A., & Storb, R. (2002) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2002.v8.pm12374456 · Cited by 251
Self-citationPetraitis, V., Petraitiene, R., Sarafandi, A. A., Kelaher, A. M., Lyman, C. A., Casler, H. E., Sein, T., Groll, A. H., Bacher, J., Avila, N. A., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/375420 · Cited by 233
de Wet, N., Cuentas, A. L., Suleiman, J., Baraldi, E., Krantz, E. F., Della Negra, M., & Diekmann-Berndt, H. (2004) · Clinical Infectious Diseases · doi:10.1086/423377 · Cited by 204
Grow, W., Moreb, J., Roque, D., Manion, K., Leather, H., Reddy, V, Khan, S., Finiewicz, K., Nguyen, H., Clancy, C., et al. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703332 · Cited by 192
Steinbach, W. J., Stevens, D. A., & Denning, D. W. (2003) · Clinical Infectious Diseases · doi:10.1086/376524 · Cited by 192
Self-citationOstrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Self-citationCornet, M., Fleury, L., Maslo, C., Bernard, J.-F., & Brücker, G. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1258 · Cited by 169
Kohno, S., Masaoka, T., Yamaguchi, H., Mori, T., Urabe, A., Ito, A., Niki, Y., & IKEMOTO, H. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020406 · Cited by 154
Hiemenz, J., Cagnoni, P. J., Simpson, D., Devine, S. M., Chao, N. J. A., Keirns, J. J., Lau, W. M., Facklam, D., & Buell, D. N. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1331-1336.2005 · Cited by 150
Self-citationIkeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.614-618.2000 · Cited by 147
Wet, N. T. E. D., Bester, A. J., Viljoen, J., Filho, F. A. B. D. O., Suleiman, J. M. A. H., Ticona, E., Llanos, E. A., Fisco, C., Lau, W. M., & Buell, D. N. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02427.x · Cited by 145
Self-citationChiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3310-3321.2001 · Cited by 117
Disseminated Aspergillosis in Intensive Care Unit Patients: An Autopsy Study
Dimopoulos, G., Piagnerelli, M., Berré, J., Eddafali, B., Salmon, I. J., & Vincent, J. (2003) · Journal of Chemotherapy · doi:10.1179/joc.2003.15.1.71 · Cited by 106
Pulmonary Infiltrates in Patients Receiving Long-term Glucocorticoid Treatment*
Agustı́, C., Rañó, A., Filella, X., González, J., Moreno, A., Xaubet, A., & Torres, A. (2003) · CHEST Journal · doi:10.1378/chest.123.2.488 · Cited by 96
A 7-year study of severe hospital-acquired pneumonia requiring ICU admission
Vallés, J., Mesalles, E., Mariscal, D., et al. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-2008-4 · Cited by 91
Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis
Matsumoto, S., Wakai, Y., Nakai, T., Hatano, K., Ushitani, T., Ikeda, F., Tawara, S., Goto, T., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.619-621.2000 · Cited by 89
Jantunen, E., Salonen, J. H., Juvonen, E., Koivunen, E., Siitonen, T., Lehtinen, T., Kuittinen, O. M., Leppä, S., Anttila, V.-J., Itälä, M., et al. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00273.x · Cited by 77
Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent
Pettengell, K., Mynhardt, J., Kluyts, T., Lau, W. M., Facklam, D., Buell, D. N., & the FK463 South African Study Group (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02083.x · Cited by 76
Self-citationWarn, P. A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg185 · Cited by 68
Chandrasekar, P. H., Cutright, J. L., & Manavathu, E. K. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00958.x · Cited by 60
Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin
Graybill, J. R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg425 · Cited by 55
California Pacific Medical Center
Pace, T. T. (1992) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199201000-00025 · Cited by 41
Micafungin: a therapeutic review
Higashiyama, Y., & Kohno, S. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.3.345 · Cited by 34 · cited 2×
“Micafungin (FK463) is a new lipopeptide compound (echinocandin) synthesized through the chemical modification of a product from Coleophoma empetri.(20,21) Its antifungal activity resides at the cell wall as it inhibits the synthesis of (1,3)-beta-D-glucan.”
BackgroundInvasive Aspergillosis in Italian AIDS Patients
Libanore, M., Prini, E., Mazzetti, M., et al. (2002) · Infection · doi:10.1007/s15010-002-2033-1 · Cited by 31
Choi, J., Brummer, E., & Stevens, D. A. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2003.12.010 · Cited by 29
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationAspergillus flavus: human pathogen, allergen and mycotoxin producer
Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., & Denning, D. W. (2007) · Microbiology · doi:10.1099/mic.0.2007/007641-0 · Cited by 964
Self-citationPulmonary aspergillosis: a clinical review
Kousha, M., Tadi, R., & Soubani, A. O. (2011) · European Respiratory Review · doi:10.1183/09059180.00001011 · Cited by 752
Metadata
- Authors
- Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D. P., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J.-A. H., Buell, D. N., & Patterson, T. F.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 53
- Issue
- 5
- Pages
- 337-349
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W1968047266
- Cited by
- 294
- References
- 44
- FWCI
- 19.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.